The global aging population—projected to reach 1.5 billion people over 65 by 2050—is profoundly impacting the Human Growth Hormone Market. While older adults increasingly require HGH for medical conditions like sarcopenia (muscle loss) and osteoporosis, a subset seeks it for anti-aging, creating a dual demand that challenges market stakeholders. This tension between medical...